---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002750"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T11:00:12.044109+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Theriva Biologics announces investor presentations with updated corporate deck

## Summary
- Company to present to investors over next several weeks; updated deck filed as Exhibit 99.1.
- Presentation titled 'Unique Oncolytic Virus Therapies for Multiple Solid Tumors' dated Jan 2026.
- CEO Steven Shallcross signed the filing; stock trades on NYSE American under TOVX.
- No specific financial or clinical data disclosed in the filing or exhibit text provided.

## SEC filing metadata
- accession: 0001104659-26-002750
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/0001104659-26-002750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/tm262896d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002750
- JSON: https://secwatch.observer/filing/0001104659-26-002750.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.